Inhibitors of programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) have shown promising antitumor effects in various cancers, including non-small-cell lung cancer (NSCLC) [6]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.